Intensity Therapeutics

The provided content does not contain any readable text for summarization.

Intensity Therapeutics, Inc. is pioneering localized cancer reduction with its lead product, INT230-6, which activates systemic anti-cancer immune response. The company's unique approach involves direct tumor injection, avoiding systemic spread and minimizing side effects. Clinical studies on INT230-6 are progressing, with Phase 3 trials in soft tissue sarcoma and Phase 2/3 in triple-negative breast cancer. Intensity aims to address challenges through extensive training for investigators and precise dosing, with a focus on achieving favorable safety and extended patient survival.

Intensity Therapeutics, Inc. (NASDAQ: INTS) has entered into a securities purchase agreement for a registered direct offering and concurrent private placement, expected to generate approximately $3 million in gross proceeds. The company announced the sale of 1,237,113 common shares at $2.425 each to a healthcare-focused institutional investor, alongside warrants for an additional 1,237,113 shares at $2.95 per share. The offerings aim to bolster the company's working capital and are scheduled to close on November 22, 2024. Intensity Therapeutics is pioneering intratumoral injections for cancer therapies and is conducting various clinical trials, including Phase 3 for soft tissue sarcoma and Phase 2/3 for triple-negative breast cancer.

Intensity Therapeutics reports Q3 2024 financials and updates on Phase 3 INVINCIBLE-3 study for soft tissue sarcoma and Phase 2 INVINCIBLE-4 study for triple-negative breast cancer. The company received regulatory approvals to initiate studies in eight countries and dosed the first patient in the INVINCIBLE-4 study. Net loss was $3.5 million for Q3 2024.

Intensity Therapeutics and SAKK collaborate on INVINCIBLE-4 Study, a Phase 2 trial evaluating INT230-6 combined with SOC vs. SOC alone in localized TNBC, with the primary endpoint being pathological complete response rates.